Bioequivalence Study of Amoxicillin-Clavulanic Acid 600 mg - 42.9 mg/ 5 mL Oral Suspension Under Fasting Conditions
NCT ID: NCT00778414
Last Updated: 2008-10-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
48 participants
INTERVENTIONAL
2006-06-30
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A total of 55 healthy, adult subjects signed the study - specific Informed Consent Form and were confined for Period I; of these subjects, 48 (24 males and 24 females) were enrolled and were dosed in the study; 42 of these enrolled subjects completed the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension of ranbaxy
Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension
2
Augmentin ES - 600
Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male or female, smoker or non - smoker, 18 years of age or older
2. Capable of consent
3. BMI should be greater than, or equal to 19.0 and less than 30.0
Exclusion Criteria
1. Clinically significant illness or surgery within 4 weeks prior to dosing
2. Any clinically significant abnormality or abnormal laboratory test results found during medical screening
3. Any reason which, in the opinion of the Clinical Sub - Investigator, would prevent the subjects from participating in the study
4. Positive test for hepatitis B, hepatitis C or HIV at screening
5. ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening
6. History of significant alcohol abuse or drug abuse within one year prior to the screening
7. Regular use of alcohol within six months prior to the screening visit (more than fourteen units of alcohol per week \[ 1 unit = 150 mL of wine, 360 mL of beer, 0r 45 mL of 40% alcohol\])
8. Use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine \[PCP\] and crack) within 1 year prior to the screening visit or positive urine drug screen at screening
9. History of allergic reactions to amoxicillin - clavulanic acid, penicillin, or other related drugs
10. Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, Omeprazole; examples of inhibitors: antidepressants (SSRI), cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolines, antihistamines) within 30 days prior to administration of the study medication
11. Use of an investigational drug or participation in an investigational study within 30 days prior to dosing
12. Clinically significant history or presence of any gastrointestinal pathology (e.g.: chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms (e.g.: diarrhea, vomiting) liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism or excretion of the drug.
13. Any clinically significant history or presence of neurological, endocrinal, cardiovascular, pulmonary, hematological, immunologic, psychiatric, or metabolic disease
14. Use of the prescription medication within 14 days prior to the administration of study medication or over - the - counter products (including natural food supplements, vitamins, garlic as a supplement) within 7 days prior to the administration of the study medication, except for topical products without systemic absorption and hormonal contraceptives
15. Difficulty to swallow the study medication
16. Smoking more than 25 cigarettes per days
17. Any food allergy, intolerance, restriction or special diet that, in the opinion of the Clinical Sub-Investigator, could contraindicate the subject's participation in this study
18. A depot injection or an implant of any drug (other than hormonal contraceptives) within 3 months prior to administration of the study medications
19. Donation of plasma (500 mL) within 7 days prior to the drug administration. Donation or loss of whole blood (excluding the volume of blood that will be drawn during the screening procedures for this study) prior to administration of the study medication as follows:
* 50 mL to 599 mL of whole blood within 30 days
* More than 499 ml of whole blood within 56 days prior to the drug administration t) Wear of dentures or presence of braces at the time of dosing or any piercing in mouth, lips, and/ or tongue u) Positive urine pregnancy test at screening v) Breast feeding subject w) Female subjects of child bearing potential having unprotected sexual intercourse with any non - sterile male partner (i.e. male who have not been sterilized by vasectomy for at least 6 months) within 14 days prior to study drug administration. Hormonal contraceptives are permitted during the study but are not an acceptable method of contraception. Acceptable methods of contraception are:
* intra-uterine contraceptive device (placed at least 4 weeks prior to study drug administration)
* Condom or diaphragm + spermicide
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ranbaxy Laboratories Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ranbaxy Research Labs
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anapharm
Québec, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Related Info
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
60249
Identifier Type: -
Identifier Source: org_study_id